Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 8/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19723355 | 0.80 | PDGFRB (0.50) | PDGFRBPDGFRANPC1RAB9ADYRK1A | |
| SCHEMBL29699377 | 0.80 | CYP2A6 (0.39) | PDGFRBPDGFRANR4A2KDRBACE1 | |
| SCHEMBL29699553 | 0.76 | PDGFRB (0.43) | PDGFRBPDGFRANR4A2DAOKDR | |
| SCHEMBL23457521 | 0.76 | PDGFRB (0.43) | PDGFRBPDGFRANR4A2DAOKDR | |
| SCHEMBL31014250 | 0.73 | CDK8 (0.55) | PDGFRBPDGFRAKDRDYRK1APIK3CG | |
| SCHEMBL5612785 | 0.71 | RPA1 (0.44) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30644240 | 0.71 | PDGFRB (0.73) | PDGFRBPDGFRANR4A2ESR2NPC1 | |
| SCHEMBL5667402 | 0.71 | PDGFRB (0.73) | PDGFRBPDGFRANR4A2ESR2NPC1 | |
| SCHEMBL31060338 | 0.70 | PDGFRB (1.00) | PDGFRBPDGFRANR4A2ESR2DYRK1A | |
| SCHEMBL23457543 | 0.70 | RPA1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | PDGFRB 4727/4885PDGFRA 4752/4885NR4A2 3882/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | PDGFRB 4792/4885PDGFRA 4815/4885NR4A2 3770/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | PDGFRB 4727/4885PDGFRA 4752/4885NR4A2 3882/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | PDGFRB 4727/4885PDGFRA 4752/4885NR4A2 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.